Company intelligence / Profile preview
Epizon Pharma, Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
Epizon Pharma, Inc. is developing novel therapies for microvascular calcification using long-active derivatives of Vitamin K2. Their lead candidate EPN‑701 (menaquinone‑7) has completed a Phase 2 clinical trial in patients with end-stage renal disease on hemodialysis to assess safety, pharmacokinetics, and biomarker effects. The company has also been granted a US patent for methods and compositions for preventing or treating tissue calcification. Clinical results have not yet been publicly posted as of early 2025.
- Therapeutic areas
- Metabolic DisordersNephrology
- Modalities
- Small molecules (specifically menaquinone-7/Vitamin K2 derivatives)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Epizon Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epizon Pharma, Inc..